ACLC 2024 Highlights Webinar-ACLC 2024 Highlights Webinar

Video Transcription

Video Summary

The ISLC webinar, presented by Dr. Hidehito Horinouchi and co-moderated with Dr. Calvin Ng, outlined significant findings from the 2024 International Association for the Study of Lung Cancer (ISLC) conference. Key presentations included Dr. Tetsuya Misudomi discussing the long-term efficacy of neoadjuvant nivolumab combined with chemotherapy in resectable non-small cell lung cancer. The four-year data from Checkmate 816 showed promising trends, particularly in the Asian subset, although complete statistical significance remains unreached. Operational challenges such as surgical cancellations and patient stratification were highlighted. Dr. Fei-Fei Huang presented a study on mobile low-dose CT and AI for lung cancer screening in underserved areas, showcasing its feasibility and cost-effectiveness in early detection. Challenges such as funding and logistics were addressed. Lastly, Dr. Matthew Smeltzer spoke about global disparities in biomarker testing, with a focus on cost and access being major barriers, especially in low-to-middle-income countries. Solutions proposed included increasing awareness and improving healthcare policies. The webinar underscored the ongoing challenges and advancements in lung cancer detection and management globally.

Asset Subtitle

Video

Meta Tag

Concept Nivolumab

Concept Event-Free Survival

Concept Mobile Low-Dose CT Screening

Concept Biomarker Testing

Concept Resectable Stage II-III Non-Small Cell Lung Cancer

Keywords

ISLC webinar

lung cancer

neoadjuvant nivolumab

Checkmate 816

mobile low-dose CT

AI screening

biomarker testing

global disparities

healthcare policies

Nivolumab

Event-Free Survival

Mobile Low-Dose CT Screening

Biomarker Testing

Resectable Stage II-III Non-Small Cell Lung Cancer